Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-CD38 dual-target autologous CAR-T cells
- Development stage
- Phase 2
- Lead developer
- Shenzhen Nanshan People's Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA-CD38 dual-target autologous CAR-T cells are an investigational cell therapy being evaluated for the treatment of relapsed or refractory multiple myeloma. This autologous therapy involves engineering a patient's own T cells to express chimeric antigen receptors (CARs) that simultaneously target two antigens commonly found on myeloma cells: B-cell maturation antigen (BCMA) and CD38. By targeting two antigens, the therapy aims to overcome potential antigen escape mechanisms and improve the depth and durability of response compared to single-target CAR-T therapies. Clinical development is being led by academic institutions including Shenzhen Nanshan Hospital and Huazhong University of Science and Technology, with trials demonstrating safety and efficacy in patients who have failed multiple prior lines of therapy.
- Other names
- BCMA/CD38 dual-targeting CAR-T cellsanti-BCMA/CD38 CAR-T cellsBCMA-CD38 dual-target autologous CAR-T cellsBCMA-CD-38 dual-target autologous CAR-T cellsBCMA-CD 38 dual-target autologous CAR-T cells
02
Targets
BCMA (B-cell maturation antigen)CD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on BCMA-CD38 dual-target autologous CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-CD38 dual-target autologous CAR-T cells.